{
    "organizations": [],
    "uuid": "14d9b75d4669e3bd4254d0427bb67054bad01ddb",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mallinckrodt-reports-on-fda-joint/brief-mallinckrodt-reports-on-fda-joint-advisory-committee-meeting-for-stannsoporfin-idUSFWN1SA1E7",
    "ord_in_thread": 0,
    "title": "Mallinckrodt Reports On FDA Joint Advisory Committee Meeting For Stannsoporfin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - Mallinckrodt Plc:\n* MALLINCKRODT REPORTS ON FDA JOINT ADVISORY COMMITTEE MEETING FOR STANNSOPORFIN FOR THE TREATMENT OF NEWBORNS AT RISK OF DEVELOPING SEVERE JAUNDICE\n* FDA COMMITTEE RECOMMENDED RISK-BENEFIT PROFILE OF STANNSOPORFIN DOES NOT SUPPORT APPROVAL FOR TREATMENT OF NEWBORNS â‰¥35 WEEKS OF GESTATIONAL AGE\n* GIVEN THE OUTCOME OF MEETING, THE COMPANY IS EVALUATING ALTERNATIVES FOR THIS DEVELOPMENT PROGRAM Source text for Eikon:\nOur ",
    "published": "2018-05-04T06:57:00.000+03:00",
    "crawled": "2018-05-04T16:51:09.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "mallinckrodt",
        "plc",
        "mallinckrodt",
        "report",
        "fda",
        "joint",
        "advisory",
        "committee",
        "meeting",
        "stannsoporfin",
        "treatment",
        "newborn",
        "risk",
        "developing",
        "severe",
        "jaundice",
        "fda",
        "committee",
        "recommended",
        "profile",
        "stannsoporfin",
        "support",
        "approval",
        "treatment",
        "newborn",
        "week",
        "gestational",
        "age",
        "given",
        "outcome",
        "meeting",
        "company",
        "evaluating",
        "alternative",
        "development",
        "program",
        "source",
        "text",
        "eikon"
    ]
}